BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 3884712)

  • 21. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells.
    Uckun FM; Gajl-Peczalska K; Meyers DE; Ramsay NC; Kersey JH; Colvin M; Vallera DA
    Blood; 1987 Jan; 69(1):361-6. PubMed ID: 3098325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
    Vallera DA; Uckun FM
    Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
    [No Abstract]   [Full Text] [Related]  

  • 23. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
    [No Abstract]   [Full Text] [Related]  

  • 24. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
    Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
    Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo elimination of neoplastic T-cells from human marrow using an anti-Mr 41,000 protein immunotoxin: potentiation by ASTA Z 7557.
    Uckun FM; Ramakrishnan S; Houston LL
    Blut; 1985 Jan; 50(1):19-23. PubMed ID: 3881146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
    De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
    Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin.
    Krönke M; Schlick E; Waldmann TA; Vitetta ES; Greene WC
    Cancer Res; 1986 Jul; 46(7):3295-8. PubMed ID: 3011246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
    Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.
    Kvalheim G; Fodstad O; Pihl A; Nustad K; Pharo A; Ugelstad J; Funderud S
    Cancer Res; 1987 Feb; 47(3):846-51. PubMed ID: 3492268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK
    Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
    Tamayo E; Hervé P
    Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
    Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
    Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
    Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
    J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
    Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous bone-marrow transplantation for Burkitt's lymphoma: marrow purging with anti-Y 29/55 monoclonal antibody and complement.
    Baumgartner C; Delaleu B; Imbach P; Lüthy A; Odavic R; Brun del Re G; Bucher U; Forster HK; Hirt A; Wagner HP
    IARC Sci Publ; 1985; (60):435-40. PubMed ID: 3905594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
    Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of malignant clonogenic breast cancer cells from human bone marrow.
    Anderson IC; Shpall EJ; Leslie DS; Nustad K; Ugelstad J; Peters WP; Bast RC
    Cancer Res; 1989 Aug; 49(16):4659-64. PubMed ID: 2663144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limiting dilution analysis for detection of residual leukemic cells after bone marrow combined decontamination with mafosfamide followed by merocyanine-540-mediated photosensitization.
    Porcellini A; Rossi MT; Manna A; Sparaventi G; Pazzaglia C
    Int J Cell Cloning; 1989 Jul; 7(4):223-31. PubMed ID: 2671163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
    Bast RC; Ritz J; Lipton JM; Feeney M; Sallan SE; Nathan DG; Schlossman SF
    Cancer Res; 1983 Mar; 43(3):1389-94. PubMed ID: 6337707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.